HERO demonstrated that Orgovyx was superior to Lupron in maintaining castration from day 29 up to week 48. Orgovyx also showed an almost a five-fold reduction in the risk of subsequent major cardiac events, a concern for men on Lupron.
Understanding the Recent Advances in Treating Castrate Sensitive Prostate Cancer
Abiraterone, enzalutamide, apalutamide, and docetaxel could be considered for this patient population (castrate sensitive prostate cancer patients), noted Taplin. "None of us can [confirm] that one [option] is better than the other; [the treatment decision] needs to be individualized [by weighing the] pros and cons [with each agent] for each patient," Taplin concluded.
